share_log

HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target

Moomoo 24/7 ·  Mar 26 11:12

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment